NOTICE For Investors In NASDAQ: GOSS: Lawsuit against Gossamer Bio, Inc. announced by Shareholders Foundation

San Diego, California--(Newsfile Corp. - April 20, 2020) -  The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ: GOSS shares.

Investors, who purchased shares of Gossamer Bio, Inc. (NASDAQ: GOSS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On April 3, 2020, a lawsuit was filed against Gossamer Bio, Inc over alleged Securities Laws Violations. The plaintiff alleges that certain materials supporting Gossamer's initial public offering ("IPO"), and certain of Gossamer's post-IPO public filings, misled investors or otherwise omitted material facts relevant to Gossamer's GB001 drug and its related clinical trials and studies.

More specifically, the plaintiff alleges that the Defendants misrepresented and/or failed to disclose to investors: (1) the reasons for Gossamer's GB001 trial failures; (2) the purported clinical validation of Novartis'oral DP2 antagonist; and (3) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

Those who purchased Gossamer Bio, Inc. (NASDAQ: GOSS) shares should contact the Shareholders Foundation, Inc.

CONTACT:

Shareholders Foundation, Inc. 
Michael Daniels 
+1 (858) 779-1554 
mail@shareholdersfoundation.com 
3111 Camino Del Rio North 
Suite 423 
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/54613